24/7 is focused on the application of chemistry, biology and materials science to the discovery, development, formulation, manufacture and commercialization of pharmaceuticals, biotherapeutics, diagnostics and other supporting products and services within the life sciences sector.
The first issue of 24/7 (former Life Sciences Knowledge Hub), was published in 2021.
The magazine is published online, with print issues being produced for distribution at industry events. The total readership is about 85K+ life sciences executives, with about 40% of these based in Europe, 40% based in the USA, and 20% based in Asia (mainly in India, China and Japan). This readership is comprised of middle- and senior-level managers in companies specializing in fine chemicals, contract manufacture, formulation, small-molecule therapeutics (from start-ups to Big Pharma), biotechnology (from technology platform developers through contract manufacture to biotherapeutics companies), diagnostics, clinical development, clinical trials management and (bio)pharmaceutical commericalization, as well as in companies providing life sciences support services.
For editorial enquiries, please email: editor@247biopharma.com
Founded in 2017, our digital platform provides rapid publication of news, feature articles, and industry event previews and reviews. As with all good innovations that are typical of our industry, 24/7 Biopharma was borne of seeing a way to “do it better”. Our digital model allows rapid publication on-line, with weekly emails to tens of thousands of colleagues working in biopharma across the globe. Top news and articles are included in special printed issues*, which are distributed at key shows that we know are important to the industry’s decision makers.
